编者按:本文来自米内网,作者苍穹;赛柏蓝授权转载,编辑晓琳2026年我国将对新机制、新靶点创新药,在沟通交流、临床试验、注册申报、审评审批全链条强化服务支持,助力创新药“中国首发”。据不完全统计,恒瑞医药的SHR4640片、悦康药业的紫花温肺止嗽颗粒、以岭药业的芪桂络痹通片、三生制药的重组红细胞生成刺激蛋白注射液(CHO细胞)......65款国产1类新药有望于今年内获批上市。2026年有望获批...
Source Link编者按:本文来自米内网,作者苍穹;赛柏蓝授权转载,编辑晓琳2026年我国将对新机制、新靶点创新药,在沟通交流、临床试验、注册申报、审评审批全链条强化服务支持,助力创新药“中国首发”。据不完全统计,恒瑞医药的SHR4640片、悦康药业的紫花温肺止嗽颗粒、以岭药业的芪桂络痹通片、三生制药的重组红细胞生成刺激蛋白注射液(CHO细胞)......65款国产1类新药有望于今年内获批上市。2026年有望获批...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.